Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

Kim Henriksen, Inger Byrjalsen, Per Qvist, Henning Beck-Nielsen, Gitte Hansen, Bente J Riis, Hans Perrild, Ole Lander Svendsen, Jeppe Gram, Morten A Karsdal, Claus Christiansen, BALLET Trial Investigators

54 Citationer (Scopus)

Abstract

Treatment of patients with perioxisome proliferator-activated receptor-γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator-activated receptor-γ agonists has not been established in a clinical trial. The BALaglitazone glucose Lowering Efficacy Trial aimed to establish the glucose-lowering effects and safety parameters of the perioxisome proliferator-activated receptor-γ partial agonist balaglitazone in diabetic patients on stable insulin therapy.
OriginalsprogEngelsk
TidsskriftDiabetes - Metabolism: Research and Reviews (Print Edition)
Vol/bind27
Udgave nummer4
Sider (fra-til)392-401
Antal sider10
ISSN1520-7552
DOI
StatusUdgivet - 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy'. Sammen danner de et unikt fingeraftryk.

Citationsformater